Your browser doesn't support javascript.
Changes in the Rate of Leucine-Rich Glioma-Inactivated 1 Seropositivity During the COVID-19 Lockdown.
Handel, Adam E; Palace, Jacqueline; Bateman, Elizabeth; Waters, Patrick; Irani, Sarosh R.
  • Handel AE; Department of Clinical Neurology, John Radcliffe Hospital, Oxford, United Kingdom.
  • Palace J; Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
  • Bateman E; Department of Clinical Neurology, John Radcliffe Hospital, Oxford, United Kingdom.
  • Waters P; Department of Clinical Immunology, John Radcliffe Hospital, Oxford, United Kingdom.
  • Irani SR; Department of Clinical Neurology, John Radcliffe Hospital, Oxford, United Kingdom.
JAMA Neurol ; 80(4): 419-420, 2023 04 01.
Article in English | MEDLINE | ID: covidwho-2241304
This case-control study investigates the positivity rates of the most prevalent neuroglial surface antibodies during the COVID-19 pandemic.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Glioma Type of study: Observational study Limits: Humans Language: English Journal: JAMA Neurol Year: 2023 Document Type: Article Affiliation country: Jamaneurol.2022.5346

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Glioma Type of study: Observational study Limits: Humans Language: English Journal: JAMA Neurol Year: 2023 Document Type: Article Affiliation country: Jamaneurol.2022.5346